Relapse prevention in schizophrenia: A systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics

Taishiro Kishimoto, V. Agarwal, T. Kishi, S. Leucht, J. M. Kane, C. U. Correll

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Few controlled trials compared second-generation antipsychotics (SGAs) with first-generation antipsychotics (FGAs) regarding relapse prevention in schizophrenia. We conducted a systematic review/meta-analysis of randomized trials, lasting 6 months comparing SGAs with FGAs in schizophrenia. Primary outcome was study-defined relapse; secondary outcomes included relapse at 3, 6 and 12 months; treatment failure; hospitalization; and dropout owing to any cause, non-adherence and intolerability. Pooled relative risk (RR) (±95% confidence intervals (CIs)) was calculated using random-effects model, with numbers-needed-to-treat (NNT) calculations where appropriate. Across 23 studies (n4504, mean duration61.9±22.4 weeks), none of the individual SGAs outperformed FGAs (mainly haloperidol) regarding study-defined relapse, except for isolated, single trial-based superiority, and except for risperidone's superiority at 3 and 6 months when requiring 3 trials. Grouped together, however, SGAs prevented relapse more than FGAs (29.0 versus 37.5%, RR0.80, CI: 0.70-0.91, P0.0007, I 2 37%; NNT17, CI: 10-50, P0.003). SGAs were also superior regarding relapse at 3, 6 and 12 months (P0.04, P0.0001, P0.0001), treatment failure (P0.003) and hospitalization (P0.004). SGAs showed trend-level superiority for dropout owing to intolerability (P0.05). Superiority of SGAs regarding relapse was modest (NNT17), but confirmed in double-blind trials, first- and multi-episode patients, using preferentially or exclusively raw or estimated relapse rates, and for different haloperidol equivalent comparator doses. There was no significant heterogeneity or publication bias. The relevance of the somewhat greater efficacy of SGAs over FGAs on several key outcomes depends on whether SGAs form a meaningful group and whether mid- or low-potency FGAs differ from haloperidol. Regardless, treatment selection needs to be individualized considering patient- and medication-related factors.

Original languageEnglish
Pages (from-to)53-66
Number of pages14
JournalMolecular Psychiatry
Volume18
Issue number1
DOIs
Publication statusPublished - 2013 Jan
Externally publishedYes

Fingerprint

Secondary Prevention
Antipsychotic Agents
Meta-Analysis
Schizophrenia
Recurrence
Haloperidol
Confidence Intervals
Treatment Failure
Hospitalization
Numbers Needed To Treat
Publication Bias
Risperidone

Keywords

  • antipsychotics
  • long-term treatment
  • maintenance
  • meta-analysis
  • relapse prevention
  • schizophrenia

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Relapse prevention in schizophrenia : A systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. / Kishimoto, Taishiro; Agarwal, V.; Kishi, T.; Leucht, S.; Kane, J. M.; Correll, C. U.

In: Molecular Psychiatry, Vol. 18, No. 1, 01.2013, p. 53-66.

Research output: Contribution to journalArticle

@article{ebc6eac9b64647868969591f70fb22df,
title = "Relapse prevention in schizophrenia: A systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics",
abstract = "Few controlled trials compared second-generation antipsychotics (SGAs) with first-generation antipsychotics (FGAs) regarding relapse prevention in schizophrenia. We conducted a systematic review/meta-analysis of randomized trials, lasting 6 months comparing SGAs with FGAs in schizophrenia. Primary outcome was study-defined relapse; secondary outcomes included relapse at 3, 6 and 12 months; treatment failure; hospitalization; and dropout owing to any cause, non-adherence and intolerability. Pooled relative risk (RR) (±95{\%} confidence intervals (CIs)) was calculated using random-effects model, with numbers-needed-to-treat (NNT) calculations where appropriate. Across 23 studies (n4504, mean duration61.9±22.4 weeks), none of the individual SGAs outperformed FGAs (mainly haloperidol) regarding study-defined relapse, except for isolated, single trial-based superiority, and except for risperidone's superiority at 3 and 6 months when requiring 3 trials. Grouped together, however, SGAs prevented relapse more than FGAs (29.0 versus 37.5{\%}, RR0.80, CI: 0.70-0.91, P0.0007, I 2 37{\%}; NNT17, CI: 10-50, P0.003). SGAs were also superior regarding relapse at 3, 6 and 12 months (P0.04, P0.0001, P0.0001), treatment failure (P0.003) and hospitalization (P0.004). SGAs showed trend-level superiority for dropout owing to intolerability (P0.05). Superiority of SGAs regarding relapse was modest (NNT17), but confirmed in double-blind trials, first- and multi-episode patients, using preferentially or exclusively raw or estimated relapse rates, and for different haloperidol equivalent comparator doses. There was no significant heterogeneity or publication bias. The relevance of the somewhat greater efficacy of SGAs over FGAs on several key outcomes depends on whether SGAs form a meaningful group and whether mid- or low-potency FGAs differ from haloperidol. Regardless, treatment selection needs to be individualized considering patient- and medication-related factors.",
keywords = "antipsychotics, long-term treatment, maintenance, meta-analysis, relapse prevention, schizophrenia",
author = "Taishiro Kishimoto and V. Agarwal and T. Kishi and S. Leucht and Kane, {J. M.} and Correll, {C. U.}",
year = "2013",
month = "1",
doi = "10.1038/mp.2011.143",
language = "English",
volume = "18",
pages = "53--66",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Relapse prevention in schizophrenia

T2 - A systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics

AU - Kishimoto, Taishiro

AU - Agarwal, V.

AU - Kishi, T.

AU - Leucht, S.

AU - Kane, J. M.

AU - Correll, C. U.

PY - 2013/1

Y1 - 2013/1

N2 - Few controlled trials compared second-generation antipsychotics (SGAs) with first-generation antipsychotics (FGAs) regarding relapse prevention in schizophrenia. We conducted a systematic review/meta-analysis of randomized trials, lasting 6 months comparing SGAs with FGAs in schizophrenia. Primary outcome was study-defined relapse; secondary outcomes included relapse at 3, 6 and 12 months; treatment failure; hospitalization; and dropout owing to any cause, non-adherence and intolerability. Pooled relative risk (RR) (±95% confidence intervals (CIs)) was calculated using random-effects model, with numbers-needed-to-treat (NNT) calculations where appropriate. Across 23 studies (n4504, mean duration61.9±22.4 weeks), none of the individual SGAs outperformed FGAs (mainly haloperidol) regarding study-defined relapse, except for isolated, single trial-based superiority, and except for risperidone's superiority at 3 and 6 months when requiring 3 trials. Grouped together, however, SGAs prevented relapse more than FGAs (29.0 versus 37.5%, RR0.80, CI: 0.70-0.91, P0.0007, I 2 37%; NNT17, CI: 10-50, P0.003). SGAs were also superior regarding relapse at 3, 6 and 12 months (P0.04, P0.0001, P0.0001), treatment failure (P0.003) and hospitalization (P0.004). SGAs showed trend-level superiority for dropout owing to intolerability (P0.05). Superiority of SGAs regarding relapse was modest (NNT17), but confirmed in double-blind trials, first- and multi-episode patients, using preferentially or exclusively raw or estimated relapse rates, and for different haloperidol equivalent comparator doses. There was no significant heterogeneity or publication bias. The relevance of the somewhat greater efficacy of SGAs over FGAs on several key outcomes depends on whether SGAs form a meaningful group and whether mid- or low-potency FGAs differ from haloperidol. Regardless, treatment selection needs to be individualized considering patient- and medication-related factors.

AB - Few controlled trials compared second-generation antipsychotics (SGAs) with first-generation antipsychotics (FGAs) regarding relapse prevention in schizophrenia. We conducted a systematic review/meta-analysis of randomized trials, lasting 6 months comparing SGAs with FGAs in schizophrenia. Primary outcome was study-defined relapse; secondary outcomes included relapse at 3, 6 and 12 months; treatment failure; hospitalization; and dropout owing to any cause, non-adherence and intolerability. Pooled relative risk (RR) (±95% confidence intervals (CIs)) was calculated using random-effects model, with numbers-needed-to-treat (NNT) calculations where appropriate. Across 23 studies (n4504, mean duration61.9±22.4 weeks), none of the individual SGAs outperformed FGAs (mainly haloperidol) regarding study-defined relapse, except for isolated, single trial-based superiority, and except for risperidone's superiority at 3 and 6 months when requiring 3 trials. Grouped together, however, SGAs prevented relapse more than FGAs (29.0 versus 37.5%, RR0.80, CI: 0.70-0.91, P0.0007, I 2 37%; NNT17, CI: 10-50, P0.003). SGAs were also superior regarding relapse at 3, 6 and 12 months (P0.04, P0.0001, P0.0001), treatment failure (P0.003) and hospitalization (P0.004). SGAs showed trend-level superiority for dropout owing to intolerability (P0.05). Superiority of SGAs regarding relapse was modest (NNT17), but confirmed in double-blind trials, first- and multi-episode patients, using preferentially or exclusively raw or estimated relapse rates, and for different haloperidol equivalent comparator doses. There was no significant heterogeneity or publication bias. The relevance of the somewhat greater efficacy of SGAs over FGAs on several key outcomes depends on whether SGAs form a meaningful group and whether mid- or low-potency FGAs differ from haloperidol. Regardless, treatment selection needs to be individualized considering patient- and medication-related factors.

KW - antipsychotics

KW - long-term treatment

KW - maintenance

KW - meta-analysis

KW - relapse prevention

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84871288077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871288077&partnerID=8YFLogxK

U2 - 10.1038/mp.2011.143

DO - 10.1038/mp.2011.143

M3 - Article

C2 - 22124274

AN - SCOPUS:84871288077

VL - 18

SP - 53

EP - 66

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 1

ER -